Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$19.91 USD
-1.07 (-5.10%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $19.91 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth F Momentum B VGM
Brokerage Reports
Arcturus Therapeutics Holdings Inc. [ARCT]
Reports for Purchase
Showing records 61 - 80 ( 142 total )
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Definitive Purchase Agreement With Israel on COVID-19 Vaccine Is a Sign of More to Come; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Recap: Expecting Key Data Readouts From COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
ARCT-021 COVID-19 mRNA Vaccine Dosing Begins in Phase 1/2 Study as Planned; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Nervous Race for Frontrunners, More Relaxed "Game" for the Runner Up
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
$275M Supply Agreement With Israel for LUNARCOV19 Vaccine; More Deals Likely; Raise PT to $78
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Vaccine Phase 1/2 Trial to Begin Imminently; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
With Little COVID Impact, Full Speed Ahead for ARCT-810 Ph1 in NZ
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Major Milestone Achieved: Arcturus Is Now a Clinical Stage mRNA Company
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Recap: LUNAR-COV19 Emerges as STARR of the Show; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
1Q20 - More Evidence for Single Shot Against COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Catalent Partnership Raises the Profile of LUNAR-COV19 as a Leading Vaccine Candidate
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E